SE448991B - Analogiforfarande for framstellning av n-acetyl-para-aminofenyl-n'acetyl-d,l-metionat som har analgetisk aktivitet - Google Patents

Analogiforfarande for framstellning av n-acetyl-para-aminofenyl-n'acetyl-d,l-metionat som har analgetisk aktivitet

Info

Publication number: SE448991B
Authority: SE; Sweden
Prior art keywords: acetyl; para; napa; aminophenyl; compound
Prior art date: 1977-05-26

Application number

SE7806038A

Other languages

English (en)

Swedish (sv)

Other versions

SE7806038L (sv

Inventor

G Margetts

R S Andrews

J Legros

Original Assignee

Sterwin Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-05-26

Filing date

1978-05-25

Publication date

1987-03-30

1978-05-25 Application filed by Sterwin Ag filed Critical Sterwin Ag

1978-11-27 Publication of SE7806038L publication Critical patent/SE7806038L/xx

1987-03-30 Publication of SE448991B publication Critical patent/SE448991B/sv

Links

238000000034 method Methods 0.000 title claims description 26
230000000202 analgesic effect Effects 0.000 title claims description 10
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 224
238000002360 preparation method Methods 0.000 claims description 23
239000002253 acid Substances 0.000 claims description 22
125000004432 carbon atom Chemical group C* 0.000 claims description 16
150000001875 compounds Chemical class 0.000 claims description 11
150000008064 anhydrides Chemical class 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 8
125000003118 aryl group Chemical group 0.000 claims description 7
125000003710 aryl alkyl group Chemical group 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
125000002877 alkyl aryl group Chemical group 0.000 claims description 4
GRDMQWRBLJZFML-UHFFFAOYSA-N bis(4-nitrophenyl) sulfite Chemical compound C1=CC([N+](=O)[O-])=CC=C1OS(=O)OC1=CC=C([N+]([O-])=O)C=C1 GRDMQWRBLJZFML-UHFFFAOYSA-N 0.000 claims description 4
125000003277 amino group Chemical group 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
150000002828 nitro derivatives Chemical class 0.000 claims description 3
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
239000000203 mixture Substances 0.000 description 52
229940126062 Compound A Drugs 0.000 description 48
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 48
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 36
210000002966 serum Anatomy 0.000 description 25
108010024636 Glutathione Proteins 0.000 description 19
238000006243 chemical reaction Methods 0.000 description 18
150000002148 esters Chemical class 0.000 description 18
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 17
229960003180 glutathione Drugs 0.000 description 17
241000700159 Rattus Species 0.000 description 16
239000003826 tablet Substances 0.000 description 16
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 13
229930182817 methionine Natural products 0.000 description 13
239000000243 solution Substances 0.000 description 13
238000012360 testing method Methods 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
-1 N-acetyl-para-amino- phenyl Chemical group 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
229960001701 chloroform Drugs 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
239000000523 sample Substances 0.000 description 8
241000282472 Canis lupus familiaris Species 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
230000007062 hydrolysis Effects 0.000 description 7
238000006460 hydrolysis reaction Methods 0.000 description 7
239000002243 precursor Substances 0.000 description 7
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
230000002255 enzymatic effect Effects 0.000 description 6
235000011389 fruit/vegetable juice Nutrition 0.000 description 6
239000000126 substance Substances 0.000 description 6
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 5
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
230000037396 body weight Effects 0.000 description 5
229960004415 codeine phosphate Drugs 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000002496 gastric effect Effects 0.000 description 5
210000000548 hind-foot Anatomy 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
239000000047 product Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
239000000725 suspension Substances 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
244000215068 Acacia senegal Species 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
229920000084 Gum arabic Polymers 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
208000000114 Pain Threshold Diseases 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
239000000205 acacia gum Substances 0.000 description 4
235000010489 acacia gum Nutrition 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000008187 granular material Substances 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
230000037040 pain threshold Effects 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000600 sorbitol Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000001754 anti-pyretic effect Effects 0.000 description 3
230000003542 behavioural effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
229960001948 caffeine Drugs 0.000 description 3
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
239000003651 drinking water Substances 0.000 description 3
235000020188 drinking water Nutrition 0.000 description 3
230000037406 food intake Effects 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
150000002431 hydrogen Chemical class 0.000 description 3
210000005229 liver cell Anatomy 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
150000003512 tertiary amines Chemical class 0.000 description 3
229940086542 triethylamine Drugs 0.000 description 3
206010011703 Cyanosis Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
206010067125 Liver injury Diseases 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
231100000460 acute oral toxicity Toxicity 0.000 description 2
239000002221 antipyretic Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000007910 chewable tablet Substances 0.000 description 2
WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000007938 effervescent tablet Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
208000001780 epistaxis Diseases 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
229930182480 glucuronide Natural products 0.000 description 2
150000008134 glucuronides Chemical class 0.000 description 2
231100000234 hepatic damage Toxicity 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
231100000334 hepatotoxic Toxicity 0.000 description 2
230000003082 hepatotoxic effect Effects 0.000 description 2
230000002631 hypothermal effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000008818 liver damage Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
229960003151 mercaptamine Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000007944 soluble tablet Substances 0.000 description 2
235000000891 standard diet Nutrition 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
ZGSZBVAEVPSPFM-HYTSPMEMSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZGSZBVAEVPSPFM-HYTSPMEMSA-N 0.000 description 1
GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
RYWSYCQQUDFMAU-UHFFFAOYSA-N Acetomenaphthone Chemical compound C1=CC=C2C(OC(=O)C)=CC(C)=C(OC(C)=O)C2=C1 RYWSYCQQUDFMAU-UHFFFAOYSA-N 0.000 description 1
102000009133 Arylsulfatases Human genes 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
239000009998 Cool-X-A Substances 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000237369 Helix pomatia Species 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020843 Hyperthermia Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
244000288157 Passiflora edulis Species 0.000 description 1
235000000370 Passiflora edulis Nutrition 0.000 description 1
IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
239000012345 acetylating agent Substances 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000000729 antidote Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
239000003849 aromatic solvent Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
STDBAQMTJLUMFW-UHFFFAOYSA-N butobarbital Chemical compound CCCCC1(CC)C(=O)NC(=O)NC1=O STDBAQMTJLUMFW-UHFFFAOYSA-N 0.000 description 1
229960003874 butobarbital Drugs 0.000 description 1
RCQXSQPPHJPGOF-UHFFFAOYSA-N caffeine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C RCQXSQPPHJPGOF-UHFFFAOYSA-N 0.000 description 1
229960002031 caffeine citrate Drugs 0.000 description 1
LCHGOKZNRDAXEK-UHFFFAOYSA-N caffeine monohydrate Chemical compound O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C LCHGOKZNRDAXEK-UHFFFAOYSA-N 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229960002810 chlormezanone Drugs 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
229960001051 dimercaprol Drugs 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
PNDDHEORJIOXJT-UHFFFAOYSA-L disodium dodecyl sulfate hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.CCCCCCCCCCCCOS([O-])(=O)=O PNDDHEORJIOXJT-UHFFFAOYSA-L 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000009950 felting Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000036031 hyperthermia Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
229940111688 monobasic potassium phosphate Drugs 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
229940099459 n-acetylmethionine Drugs 0.000 description 1
ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
MMMNTDFSPSQXJP-UHFFFAOYSA-N orphenadrine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 MMMNTDFSPSQXJP-UHFFFAOYSA-N 0.000 description 1
229960001687 orphenadrine citrate Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
229960005382 phenolphthalein Drugs 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
229960002189 propyphenazone Drugs 0.000 description 1
208000018299 prostration Diseases 0.000 description 1
BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007892 solid unit dosage form Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
108060007951 sulfatase Proteins 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012353 t test Methods 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Emergency Medicine (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SE7806038A 1977-05-26 1978-05-25 Analogiforfarande for framstellning av n-acetyl-para-aminofenyl-n'acetyl-d,l-metionat som har analgetisk aktivitet SE448991B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB22218/77A GB1583602A (en)	1977-05-26	1977-05-26	N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives

Publications (2)

Publication Number	Publication Date
SE7806038L SE7806038L (sv)	1978-11-27
SE448991B true SE448991B (sv)	1987-03-30

Family

ID=10175844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7806038A SE448991B (sv)	1977-05-26	1978-05-25	Analogiforfarande for framstellning av n-acetyl-para-aminofenyl-n'acetyl-d,l-metionat som har analgetisk aktivitet

Country Status (15)

Country	Link
US (4)	US4181719A (de)
AT (1)	AT368489B (de)
BE (1)	BE867531A (de)
CH (1)	CH644590A5 (de)
DE (1)	DE2822789C2 (de)
DK (1)	DK155832C (de)
FI (1)	FI70208C (de)
FR (1)	FR2391998A1 (de)
GB (1)	GB1583602A (de)
IE (1)	IE47072B1 (de)
IT (1)	IT1202822B (de)
LU (1)	LU79703A1 (de)
NL (1)	NL176070C (de)
NO (1)	NO146392C (de)
SE (1)	SE448991B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1111384B (it) *	1978-12-21	1986-01-13	Sigma Tau Ind Farmaceuti	Guaiacil esteri di derivati dello acido mercaptopropionico procedimento per la loro preparazione e loro uso terapeutico
US4307073A (en) *	1980-08-08	1981-12-22	The Research Foundation Of State University Of New York	Method and composition for reducing the toxicity of acetaminophen
US4504413A (en) *	1982-04-02	1985-03-12	Syva Company	Acetaminophen analogs, antigens, and antibodies
US5103021A (en) *	1982-04-02	1992-04-07	Syntex (U.S.A.) Inc.	Acetaminophen analogs, antigens, and antibodies
US4605754A (en) *	1982-04-02	1986-08-12	Syntex (U.S.A.) Inc.	Acetaminophen analogs
CH654302A5 (de) *	1983-05-04	1986-02-14	Sandoz Ag	Acylaminophenolderivate, ihre herstellung und arzneimittel, welche sie enthalten.
GB9305058D0 (en) *	1993-03-12	1993-04-28	Penn Pharm Ltd	Pharmaceutical compositions
DE19711053C2 (de) *	1997-03-03	1999-09-02	Rommelspacher	Kombinationspräparat aus 2-Methyl-thiazolidin-2,4-dicarbonsäure und Paracetamol
FR2814366A1 (fr) *	2000-09-22	2002-03-29	Rhodia Chimie Sa	Procede de granulation de matieres actives par extrusion basse pression pour l'obtention de granules directement compressibles
AU2002220248A1 (en) *	2000-11-06	2002-05-15	Andrx Pharmaceuticals, Inc.	Once a day antihistamine and decongestant formulation
GB0114069D0 (en) *	2001-06-08	2001-08-01	Smithkline Beecham Plc	Composition
US8092831B2 (en) *	2002-11-08	2012-01-10	Andrx Pharmaceuticals, Llc	Antihistamine and decongestant system
EP1603593A4 (de) *	2002-11-15	2007-08-01	Branded Products For The Futur	Pharmazeutische zusammensetzung
US20050220862A1 (en) *	2004-03-31	2005-10-06	Bernstein Joel E	Compositions with reduced hepatotoxicity
CN102088965B (zh) *	2008-05-13	2013-05-08	根梅迪卡治疗公司	水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
AU2009249071A1 (en) *	2008-05-20	2009-11-26	Neurogesx, Inc.	Hepatoprotectant acetaminophen mutual prodrugs
JP2012520342A (ja) *	2009-03-16	2012-09-06	ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ	代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
CN102421424A (zh) *	2009-03-16	2012-04-18	根梅迪卡治疗公司	用于治疗代谢性疾病的组合疗法
US8466197B2 (en)	2010-12-14	2013-06-18	Genmedica Therapeutics Sl	Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR462M (de) *	1958-10-13	1961-05-02
US3591686A (en) *	1967-08-01	1971-07-06	Mead Johnson & Co	Anti-inflammatory compositions and methods utilizing n-acylcysteines and the beta-alkyl and carboxyl derivatives thereof
US4038306A (en) *	1967-08-07	1977-07-26	Merck & Co., Inc.	N-t-butoxycarbonyl-s-lower alkanoylamidomethyl-cysteine and p-nitrophenyl esters
GB1428803A (en) *	1973-05-29	1976-03-17	Gallardo Antonio Sa	4-acetamidophenyl esters of aryl-alkane carboxylic acids and a process for their preparation
US3983138A (en) *	1973-09-25	1976-09-28	Merck & Co., Inc.	Amino acid esters
GB1463505A (en) *	1973-11-21	1977-02-02	Nat Res Dev	Pharmaceutical compositions
US3996268A (en) *	1974-09-03	1976-12-07	The Regents Of The University Of California	Cross-linking reagent for insulin synthesis

1977
- 1977-05-26 GB GB22218/77A patent/GB1583602A/en not_active Expired
1978
- 1978-05-22 FI FI781610A patent/FI70208C/fi not_active IP Right Cessation
- 1978-05-24 AT AT0380178A patent/AT368489B/de not_active IP Right Cessation
- 1978-05-24 DE DE2822789A patent/DE2822789C2/de not_active Expired
- 1978-05-25 IT IT49547/78A patent/IT1202822B/it active
- 1978-05-25 LU LU79703A patent/LU79703A1/xx unknown
- 1978-05-25 NL NLAANVRAGE7805675,A patent/NL176070C/xx not_active IP Right Cessation
- 1978-05-25 SE SE7806038A patent/SE448991B/sv not_active IP Right Cessation
- 1978-05-25 DK DK231578A patent/DK155832C/da not_active IP Right Cessation
- 1978-05-25 IE IE1047/78A patent/IE47072B1/en unknown
- 1978-05-25 NO NO781824A patent/NO146392C/no unknown
- 1978-05-26 BE BE188076A patent/BE867531A/xx not_active IP Right Cessation
- 1978-05-26 US US05/909,846 patent/US4181719A/en not_active Expired - Lifetime
- 1978-05-26 FR FR7815759A patent/FR2391998A1/fr active Granted
- 1978-05-26 CH CH578078A patent/CH644590A5/de not_active IP Right Cessation
1979
- 1979-04-02 US US06/026,329 patent/US4482495A/en not_active Expired - Lifetime
1981
- 1981-03-23 US US06/246,234 patent/US4361703A/en not_active Expired - Fee Related
1982
- 1982-03-22 US US06/360,312 patent/US4405800A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IT7849547A0 (it)	1978-05-25
US4361703A (en)	1982-11-30
FI70208C (fi)	1986-09-15
SE7806038L (sv)	1978-11-27
FI70208B (fi)	1986-02-28
CH644590A5 (de)	1984-08-15
FR2391998B1 (de)	1981-11-13
NO146392C (no)	1982-09-22
FI781610A7 (fi)	1978-11-27
DK155832C (da)	1989-10-02
IE781047L (en)	1978-11-26
IT1202822B (it)	1989-02-09
NL176070B (nl)	1984-09-17
AT368489B (de)	1982-10-11
DE2822789A1 (de)	1978-12-07
LU79703A1 (fr)	1978-11-06
NL7805675A (nl)	1978-11-28
US4482495A (en)	1984-11-13
DK231578A (da)	1978-11-27
IE47072B1 (en)	1983-12-14
US4181719A (en)	1980-01-01
NO781824L (no)	1978-11-28
DK155832B (da)	1989-05-22
GB1583602A (en)	1981-01-28
NL176070C (nl)	1985-02-18
US4405800A (en)	1983-09-20
NO146392B (no)	1982-06-14
DE2822789C2 (de)	1984-01-12
BE867531A (fr)	1978-09-18
ATA380178A (de)	1982-02-15
FR2391998A1 (fr)	1978-12-22

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 7806038-1

Effective date: 19910123

Format of ref document f/p: F

Publication	Publication Date	Title
AU2005228685B2 (en)	2010-08-19	Hydrazide-containing CFTR inhibitor compounds and uses thereof
CN100356922C (zh)	2007-12-26	囊性纤维化跨膜传导调节因子蛋白抑制剂及其用途
US4361703A (en)	1982-11-30	Para-amino(or nitro)phenyl N-acetylaminothioalkanoates
CA2938501C (fr)	2022-04-05	Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
MC2094A1 (fr)	1991-02-15	Medicament contenant de l'acide dihydrolipoique en tant que substance active,procede de preparation
TWI326687B (en)	2010-07-01	Amide prodrug of gemcitabine, compositions and use thereof
FR2837824A1 (fr)	2003-10-03	Nouveaux derives de la podophyllotoxine, leur preparation et leur application en therapeutique
JP4001636B2 (ja)	2007-10-31	ガンおよびａｉｄｓの処置のための活性化ヨード誘導体
JPH07507288A (ja)	1995-08-10	デスフェリオキサミン−ｂ塩及び経口的に有効な鉄キレート剤としてのそれらの使用
CN110156822B (zh)	2021-07-09	一种萘酚-苯硼酸类化合物及其制备方法和用途
WO1996015809A2 (en)	1996-05-30	Process for the preparation of a pharmacologically active chemical combination
US3916008A (en)	1975-10-28	Biologically active substances
CA2650480A1 (fr)	2007-11-08	Composes de type 1, 4-naphtoquinones, compositions les comprenant et utilisation de ces composes en tant qu'agents anti -cancereux
CS209857B2 (en)	1981-12-31	Method of making the new derivatives of the aminoacids
JP2002533323A (ja)	2002-10-08	メラトニン誘導体とこの誘導体を含む薬剤
RU2131247C1 (ru)	1999-06-10	Фармацевтическая композиция и производные l-аминокислот, обладающие гепатопротекторным действием
JPS58167600A (ja)	1983-10-03	アデノシン誘導体及びその製法
WO2001037823A1 (en)	2001-05-31	Substituted nitrobenzene derivatives as medicines and other useful uses thereof
US3452141A (en)	1969-06-24	Methods of treating pain with n**alpha-phthaloyl-alpha-amino acid amides
BE883963A (fr)	1980-12-23	Derives du benzimidazole et compositions pharmaceutiques les contenant
CN118772216A (zh)	2024-10-15	5-氟尿嘧啶核苷磷酰胺酯类化合物及其用途
JPH0144169B2 (de)	1989-09-26
JPH01313425A (ja)	1989-12-18	糖ラクタム誘導体及びそれを含有する癌細胞転移抑制剤
CN106317168A (zh)	2017-01-11	10-甲氧基喜树碱酯化衍生物、制备方法和用途
CH407160A (fr)	1966-02-15	Procédé de préparation de nouveaux dérivés de l'acétanilide